SCHEDULE: Laurence W. Lytton Reports 5.5% Stake in TELA Bio
Beneficial Ownership Filing
Laurence W. Lytton has disclosed beneficial ownership of 2,442,341 shares, representing 5.5% of the outstanding common stock of TELA Bio, Inc., as of March 31, 2026.
Summary
- Laurence W. Lytton has filed a Schedule 13G, indicating beneficial ownership of TELA Bio, Inc. common stock.
- The filing reports ownership of 2,442,341 shares.
- This ownership represents 5.5% of the company's outstanding common stock.
- The percentage is based on 44,740,371 shares outstanding as of March 16, 2026, as per TELA Bio's Form 10-K for the fiscal year ended December 31, 2025.
- Lytton has sole voting power and sole dispositive power over these shares.
- The filing certifies that the securities were not acquired for the purpose of influencing or changing the control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance information.
Positives
- Disclosure of a significant stake (5.5%) by Laurence W. Lytton in TELA Bio, Inc.
- Clear reporting of sole voting and dispositive power over the shares.
- Confirmation that the shares are not held with the intent to influence company control.
Future Outlook
No forward-looking statements or guidance are present in this filing, as it is a disclosure of beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant institutional or individual investors acquiring more than 5% of a public company's stock. This filing indicates Laurence W. Lytton's substantial interest in TELA Bio, Inc., a company operating in the medical technology sector, specifically focusing on advanced wound care and soft tissue reconstruction.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by Laurence W. Lytton may be of interest to existing shareholders, potentially indicating increased investor focus or confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Fiscal year end for TELA Bio, Inc. (referenced for outstanding shares calculation). |
| 2026-03-16 | Date as of which TELA Bio, Inc. reported 44,740,371 shares outstanding. |
| 2026-03-31 | Date of event requiring filing of this statement (Schedule 13G). |
| 2026-05-15 | Date of signature on the Schedule 13G filing. |
Keywords
TELA Bio, Schedule 13G, Laurence W. Lytton, Beneficial Ownership, Common Stock, SEC Filing, Shareholder, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.